TNYA - Tenaya Therapeutics, Inc.

Insider Sale by Column Group III Gp, LP (10%)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Column Group III Gp, LP, serving as 10% owner at Tenaya Therapeutics, Inc. (TNYA), sold 4,170,266 shares at $0.57 per share, for a total transaction value of $2,380,189.00. Following this transaction, Column Group III Gp, LP now holds 49,313,559 shares of TNYA.

This sale represents a 8.00% decrease in Column Group III Gp, LP's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, February 24, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, February 26, 2026, 2 days after the trade was made.

Tenaya Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Column Group III Gp, LP

Column Group III Gp, LP

10%

Column Group III GP, LP is the general partner of The Column Group III LP, a venture capital fund managed by The Column Group (TCG), a San Francisco-based firm dedicated to fueling life sciences innovation through company formation and investments across the development lifecycle.[[2]](https://aum13f.com/fund/the-column-group-iii-lp)[[5]](https://www.thecolumngroup.com/tcg-team/)[[6]](https://www.thecolumngroup.com) Established with a $239.5 million fundraise in 2016, it operates as a Venture Capital Fund focused on biotech, with offices at 1700 Owens Street, San Francisco, CA, and is audited by KPMG.[[2]](https://aum13f.com/fund/the-column-group-iii-lp) As a corporate insider, Column Group III GP, LP holds significant stakes in portfolio companies, including approximately 34% ownership in Surrozen, Inc. (SRZN) as of recent 13D/G filings (1,265,276 shares valued at around $18 million), with transactions reported in 2025, and is also a 10% owner of Revolution Medicines Inc. (RVMD) with over 5.9 million shares.[[1]](https://www.gurufocus.com/insider/126495/column-group-iii,-lp)[[3]](https://fintel.io/i/column-group-iii-gp-lp)[[4]](https://whalewisdom.com/filer/column-group-iii-gp-lp) TCG, its affiliate manager, is led by Founder and Managing Partner Peter Svennilson (35+ years in VC, founded companies sold to J&J and Roche), Managing Partner Tim Kutzkey, Ph.D. (involved in Surrozen's founding), and other partners like Haijun Chen, Ph.D., with a team of scientific and operational experts supporting investments in areas like targeted protein stabilization and therapeutics.[[5]](https://www.thecolumngroup.com/tcg-team/)

View full insider profile →

Trade Price

$0.57

Quantity

4,170,266

Total Value

$2,380,189.00

Shares Owned

49,313,559

Trade Date

Tuesday, February 24, 2026

3 days ago

SEC Filing Date

Thursday, February 26, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Tenaya Therapeutics, Inc.

Company Overview

No company information available
View news mentioning TNYA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4324654

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime